This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Maria Soloveychik, PhD
CEO at SyntheX, Inc.

Profile

Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. She is the co-inventor of the company’s core technology, ToRPPIDO - a cell-based platform that relies on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt or bridge protein-protein interactions. SyntheX was founded in 2016 and was incubated at the IndieBio accelerator in San Francisco, where Maria acts as a mentor to other startups.

Maria received her PhD from the department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium, where her work led to the determination of numerous structures and identification of several drug candidates.


Agenda Sessions

  • Using Genetic Engineering to Discover Functional Peptides for PPI Disruption and Targeted Protein Degradation

    9:50am